NCT02843490 - Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 5, 2016

Primary Completion Date

August 17, 2017

Study Completion Date

November 9, 2017

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab

Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)

Trial Locations (1)

55131

Clinical Trial Site, Department of Ophthalmology, University Medical Center Johannes Gutenberg University Mainz, Mainz